Selective JAK1 Inhibition Using Upadacitinib for the Management of Inflammatory Bowel Diseases: The Powerful Pill. (2023). Canadian IBD Today, 1(S11), 2–11. https://doi.org/10.58931/cibdt.2023.1S1121